REMARKS

Information Disclosure Statement

The applicants have also filed an IDS which acknowledges the filing of U.S. Serial No. 09/867,835 (which was also examined by the examiner of record for the present application) which is a divisional application of Ų.S. Serial No. 09/232,738.

Although U.S. Patent 6,291,503 (SN: 09/232,738) is a parent of this application are commonly assigned, different inventive entities are involves (i.e. Markus Albers is additionally listed as an applicant in the present application). Therefore, the '503 patent could also be used as a reference under 102(e)/103(a) as it was filed prior to 29 November 2000 (see MPEP 804, especially page 800-18) and as such is also noted in the IDS for the examiner's consideration.

Objections to the Specification

It is believed that the attached amendments address the objections raised in the previous office action.

35 U.S.C. 112, first paragraph rejection

Giver that the new amendment procedures requires that all claims be recopied, for brevity's sake, the examiner is authorized to delete the term "preventing" from claim 14 if the claims are otherwise allowable. (Applicants reserve the right to continue prosecution for "preventing" cancer in a divisional application)

Obviousness-type Double Patenting (ODP) Rejection

If the ODP rejection is the only remaining issue preventing allowance of the claims, it is requested that the examiner call the undersigned so that a faxed copy of a terminal disclaimer can be sent to the examiner.

Suspension of Action

Please note that a three-month suspension of action request has also been submitted concurrent with this response.

Bayer 10,159.3-HCL Le A 33 364 US-01 Lin/SWo

Closing

Applicants also believe that this application is in condition for allowance. However, should any issue(s) of a minor nature remain, the Examiner is respectfully requested to telephone the undersigned at telephone number (212) \$08-0700 so that the issue(s) might be promptly resolved.

> Respectfully submitted, Norris, McLaughlin & Marcus, P.A.

Howard C. Lee
Howard C. Lee

Reg. No. 48,104

220 East 42nd Street 30th Floor New York, New York 10017 (212) 808-0700

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that the foregoing Amendment under 37 CFR § 1.111 (13 pages total) is being facsimile transmitted to the United States Patent and Trademark Office on the date indicated below:

Date: 13 June 2003